MitoRx Therapeutics
4 known investors
MitoRx is a preclinical-stage biotech developing MTRX31, a first-in-class small molecule that restores mitochondrial metabolism to eliminate ectopic fat in patients with metabolically unhealthy, high-risk obesity. Rather than suppressing appetite, its approach aims to deliver durable weight loss and reduce risks of type 2 diabetes, MASH, and cardiovascular disease.
BiotechLongevity
Investors · 4
Frequently asked questions
- What does MitoRx Therapeutics do?
- MitoRx is a preclinical-stage biotech developing MTRX31, a first-in-class small molecule that restores mitochondrial metabolism to eliminate ectopic fat in patients with metabolically unhealthy, high-risk obesity. Rather than suppressing appetite, its approach aims to deliver durable weight loss and reduce risks of type 2 diabetes, MASH, and cardiovascular disease.
- Who are MitoRx Therapeutics's investors?
- MitoRx Therapeutics's investors include Future Planet Capital, Oxford Investment Opportunity Network (OION), Oxford Technology Management, UK Innovation & Science Seed Fund.